Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an integrated analysis of four randomised, double-blind, placebo-controlled, clinical trials

摘要

PurposeThe influence of cardiovascular risk factors/comorbidities on response to oral once-daily tadalafil 5mg was explored in men with lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH).